|
|
The Early Years
|
1913 |
|
Nycomed begins its own production of pharmaceutical products. |
|
1925 |
|
Nycomed establishes its own pharmaceutical research activities. |
|
1937 |
|
Research expands to include organic chemistry/synthesis and later diagnostic reagents for anticoagulation treatment. |
1985 – 1999
|
1985 |
|
Named Norway's 1984 "Company of the Year" in recognition of achievements in research, international exports and profitability. |
|
1990 to 1993 |
|
Extensive acquisition programme of pharmaceutical companies in Norway, Denmark, Austria and the Benelux region. |
|
1994 |
|
Pantoprazole, a proton pump inhibitor for acid-related stomach diseases, is launched (by ALTANA Pharma) and goes on to become both ALTANA Pharma and Nycomed’s most important product. |
| 1997 to 1999 |
|
Significant reduction in exploratory research activities and new focus on product development and in-licensing. |
| 1999 |
|
Nordic Capital, a leading Scandinavian private equity firm, buys Nycomed. Licensing strategy implemented. |
1999 – 2007
|
2002 |
|
Secondary buy-out by a consortium of investors led by CSFB Private Equity. First pan-European in-licensing deal (Angiox™). |
|
2003 to 2004 |
|
Nycomed assumes full ownership of Oy Leiras Finland Ab; European marketing coverage expanded by entering the UK/Ireland, Italy and Poland. |
| 2004 |
|
TachoSil® (haemostatic surgical patch), a fixed combination of a collagen sponge coated with coagulation factors, is launched. |
| 2005 |
|
Alvesco® (ciclesonide), a new generation of inhaled corticosteroid for respiratory diseases, and Angiox®, a direct thrombin inhibitor used during PCI, are both launched. |
| 2006 |
|
On 21st September 2006 Nycomed acquires ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG. |
|
|
In October 2006, Preotact®, an anabolic agent for severe osteoporosis, is launched. |
| 2007 |
|
Matrifen®, a transdermal patch for severe pain, is launched. |
|